Health Discovery Corporation: Four Genes Comprising the New Molecular Diagnostic Signature for Prostate Cancer Successfully Identified in Urine

SAVANNAH, Ga., Nov 6, 2008 (GlobeNewswire via COMTEX) -- Health Discovery Corporation ("HDC") (HDVY:0.05, 0.00, -2.9%) today announced that the RT-PCR assay for the four genes comprising HDC's recently commercialized gene-based molecular diagnostic test for prostate cancer, which is currently available at Clarient Inc.'s (CLRT: 1.55, +0.01, +0.7%) Clinical Laboratory, can be successfully used in urine samples for gene testing.